SQL - SeqLL Inc. Stock Price, Fair Value and News

4.00USD-0.50 (-11.11%)Market Closed

Market Summary

USD4.00-0.50

Market Closed

-11.11%

SQL Stock Price

View Fullscreen

SQL RSI Chart

SQL Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

19.36

Price/Free Cashflow

-0.3

SQL Price/Sales (Trailing)

SQL Profitability

Return on Equity

-925.98%

Return on Assets

-126.85%

Free Cashflow Yield

-332.76%

SQL Fundamentals

SQL Revenue

Revenue (TTM)

78.7K

SQL Earnings

Earnings (TTM)

-5.6M

Earnings Growth (Yr)

-0.44%

Earnings Growth (Qtr)

2.07%

Breaking Down SQL Revenue

Last 7 days

-10.7%

Last 30 days

-20.8%

Last 90 days

-77.7%

Trailing 12 Months

-74.7%

How does SQL drawdown profile look like?

SQL Financial Health

Current Ratio

1.08

SQL Investor Care

Shares Dilution (1Y)

9.65%

Diluted EPS (TTM)

-15.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	189.0K	152.2K	115.4K	78.7K
2021	289.0K	248.6K	208.1K	167.6K
2020	0	0	0	329.5K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SeqLL Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 19, 2022	miscoll douglas patrick	bought	495	0.33	1,500	-
Dec 16, 2022	miscoll douglas patrick	bought	525	0.35	1,500	-
Dec 09, 2022	jones daniel robert	bought	2,236	0.3901	5,733	chief executive officer
Sep 27, 2022	miscoll douglas patrick	bought	774	0.774	1,000	-
Sep 26, 2022	miscoll douglas patrick	bought	637	0.75	850	-
Sep 26, 2022	jones daniel robert	bought	3,946	0.78932	5,000	chief executive officer
Sep 23, 2022	miscoll douglas patrick	bought	114	0.76	150	-

Which funds bought or sold SQL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-1,087	-	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-526	-	-%
Feb 14, 2024	CLEAR STREET LLC	unchanged	-	-2,000	1,000	-%
Feb 14, 2024	Cruiser Capital Advisors, LLC	unchanged	-	-521	1,236	-%
Feb 14, 2024	Shay Capital LLC	sold off	-100	-502	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-1,520	-	-%
Feb 13, 2024	MORGAN STANLEY	sold off	-100	-14,698	-	-%
Feb 09, 2024	UBS Group AG	sold off	-100	-2,204	-	-%
Feb 09, 2024	WELLS FARGO & COMPANY/MN	sold off	-100	-30.00	-	-%
Feb 09, 2024	CITIGROUP INC	sold off	-100	-15.00	-	-%

Are Funds Buying or Selling SQL?

Are funds buying SQL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SQL

No. of Funds

Recent SEC filings of SeqLL Inc.

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	8-K	Current Report
Apr 17, 2024	POS AM	POS AM
Apr 10, 2024	10-K	Annual Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 25, 2024	8-K	Current Report
Mar 21, 2024	25-NSE	25-NSE
Feb 12, 2024	S-1/A	Initial Public Offering
Feb 12, 2024	EFFECT	EFFECT
Feb 09, 2024	S-1/A	Initial Public Offering
Feb 08, 2024	S-1/A	Initial Public Offering

Peers (Alternatives to SeqLL Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.5B	23.7B	-0.93%	6.50%	41.46	7.69	-8.94%	-35.72%
IDXX	41.5B	3.7B	-7.44%	3.05%	49.1	11.33	8.72%	24.44%
A	40.3B	6.7B	-6.59%	3.31%	32.64	5.99	-2.81%	-6.58%
DGX	14.9B	9.3B	2.40%	-4.82%	17.61	1.6	-3.29%	6.68%
MEDP	12.3B	2.0B	-1.91%	100.24%	39.22	6.24	25.57%	21.62%
CRL	11.8B	4.1B	-15.01%	24.62%	24.77	2.85	3.86%	-2.39%
NTRA	11.1B	1.1B	1.32%	82.46%	-25.45	10.22	31.99%	20.63%
EXAS	10.7B	2.5B	-11.98%	-7.20%	-52.35	4.28	19.93%	67.26%
MID-CAP
NEOG	2.6B	929.2M	-21.41%	-29.07%	1.7K	2.83	28.93%	111.61%
GH	2.1B	563.9M	-3.40%	-19.97%	-4.4	3.74	25.45%	26.76%
SMALL-CAP
CDNA	391.4M	280.3M	-28.23%	-2.96%	-2.06	1.4	-12.89%	-148.37%
ACRS	85.1M	31.2M	-5.56%	-86.21%	-0.96	2.72	5.03%	-1.81%
APDN	74.2M	9.0M	916.28%	337.00%	-10.27	8.25	-53.31%	2.21%
AWH	41.1M	9.2M	-2.92%	-32.04%	-2.46	4.49	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

SeqLL Inc. News

Latest updates

SeqLL Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-	-	-	10.00	29.00	47.00	62.00	16.00	63.00	26.00	-	-
Gross Profit	-	-	-	-	30.00	47.00	22.00	47.00	51.00	33.00	-	86.00
Operating Expenses	-0.3%	1,241	1,245	919	992	920	1,394	452	450	405	-	202
S&GA Expenses	-100.0%	-	807	490	626	585	997	361	425	387	-	171
R&D Expenses	10.2%	484	439	429	366	335	397	91.00	24.00	18.00	-	30.00
Interest Expenses	-100.0%	-	17.00	17.00	40.00	17.00	36.00	41.00	41.00	-	-	73.00
Net Income	-0.4%	-1,241	-1,236	-925	-994	-937	-1,397	-639	-252	-1,414	-154	-189
Net Income Margin	-37.4%	-71.54*	-52.06*	-36.87*	-26.08*	-17.07*	-22.10*	-11.83*	-8.09*	-6.62*	-3.17*	-
Free Cashflow	-34.3%	-1,019	-759	-900	-1,005	-1,037	-976	-841	54.00	-240	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet											(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-19.5%	4,436	5,508	6,676	8,469	8,414	9,351	10,095	11,188	10,740	12,143	-
Current Assets	-26.8%	2,730	3,730	4,825	6,699	6,635	7,512	8,249	9,366	10,424	11,851	343
Cash Equivalents	-27.7%	2,694	3,727	4,790	5,044	2,181	4,454	7,854	8,859	4,015	11,307	-
Inventory	-	-	-	-	-	166	247	247	229	224	209	203
Net PPE	-6.2%	625	667	708	562	530	549	260	255	265	278	337
Liabilities	2.0%	3,829	3,755	3,762	4,243	4,047	3,837	3,723	3,888	2,558	2,679	4,548
Current Liabilities	149.5%	2,531	1,014	957	1,472	1,228	971	835	2,354	2,558	1,034	1,011
Shareholder's Equity	-65.3%	608	1,753	2,914	4,226	4,367	5,513	6,372	7,300	8,182	9,464	-
Retained Earnings	-5.4%	-24,136	-22,894	-21,627	-20,227	-18,508	-17,272	-16,346	-15,351	-14,413	-13,016	-10,710
Additional Paid-In Capital	0.4%	24,744	24,648	24,541	24,435	22,853	22,786	22,719	22,652	22,596	22,481	6,856
Shares Outstanding	0%	381	381	347	347	331	331	297	297	297	141	122
Float	-	-	-	3,770	-	-	-	4,786,725,000	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	2.9%	-1,019	-1,049	-1,813	-1,122	-749	-899	-983	-1,030	-966	-841	54.00	-235	-	-
Share Based Compensation	-9.2%	96.00	106	106	83.00	67.00	67.00	67.00	56.00	115	215	3.00	1.00	-	-
Cashflow From Investing	100.0%	-	-2*	1,572	2,486	-1,524	-2,500	-21.84	5,875	-5,985	-	-	-5.25	-	-
Cashflow From Financing	-4.1%	-13.47	-12.94	-12.43	1,499	-	-	-	-	-338	12,085	-	-	-	-

SQL Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total revenue		$ 78,659
Cost of sales		690
Gross profit		77,969
Operating expenses
Research and development	2,253,354	1,568,266
General and administrative	3,479,155	2,506,851
Total operating expenses	5,732,509	4,075,117
Operating loss	(5,732,509)	(3,997,148)
Other (income) and expenses
Investment income	(82,665)	(44,879)
Unrealized gain on marketable equity securities		(54,508)
Realized loss (gain) on marketable equity securities	(106,051)	106,324
Interest expense, net	83,798	90,748
Net loss	(5,627,591)	(4,094,833)
Other comprehensive income
Unrealized gain on marketable debt securities		22,451
Reclassification adjustment for net gains included in net loss	(22,451)
Total comprehensive loss	$ (5,650,042)	$ (4,072,382)
Net loss per share - basic (in Dollars per share)	$ (15.03)	$ (12.38)
Weighted average common shares - basic (in Shares)	374,484	330,648
Sales
Revenue
Total revenue		$ 1,177
Grant revenue
Revenue
Total revenue		$ 77,482

SQL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 2,693,991	$ 2,180,525
Marketable securities		4,036,014
Accounts receivable, net of allowance for doubtful accounts of $24,507 and $6,016 as of December 31, 2023 and 2022, respectively	2,723	21,214
Other receivables		60,000
Inventory		165,852
Prepaid expenses	32,933	171,859
Total current assets	2,729,647	6,635,464
Other assets
Property and equipment, net	625,360	530,108
Operating lease right-of-use asset	998,346	1,129,715
Other assets	83,008	118,954
Total assets	4,436,361	8,414,241
Current liabilities
Accounts payable	522,940	622,436
Accrued expenses	375,191	495,462
Current portion of finance lease liability	59,659
Current portion of operating lease liability	198,314	110,114
Non-convertible promissory notes	1,375,000
Total current liabilities	2,531,104	1,228,012
Non-current liabilities
Finance lease liability, less current portion	51,481
Operating lease liability, less current portion	1,246,033	1,444,343
Non-convertible promissory notes - long-term		1,375,000
Total non-current liabilities	1,297,514	2,819,343
Total liabilities	3,828,618	4,047,355
Commitments and contingencies (Note 12)
Stockholders’ equity
Preferred stock, $0.00001 par value; 20,000,000 shares authorized; zero shares issued and outstanding
Common stock, $0.00001 par value; 300,000,000 shares authorized; 380,648 and 330,648 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	4	3
Additional paid-in capital	24,744,014	22,853,116
Accumulated deficit	(24,136,275)	(18,508,684)
Accumulated other comprehensive income		22,451
Total stockholders’ equity	607,743	4,366,886
Total liabilities and stockholders’ equity	$ 4,436,361	$ 8,414,241

About SeqLL Inc.

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.

CEO	Mr. Daniel Robert Jones
WEBSITE	https://seqll.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	7

SeqLL Inc. Frequently Asked Questions

What is the ticker symbol for SeqLL Inc.? What does SQL stand for in stocks?

SQL is the stock ticker symbol of SeqLL Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SeqLL Inc. (SQL)?

As of Sun Mar 31 2024, market cap of SeqLL Inc. is 1.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SQL stock?

You can check SQL's fair value in chart for subscribers.

What is the fair value of SQL stock?

You can check SQL's fair value in chart for subscribers. The fair value of SeqLL Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SeqLL Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SQL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SeqLL Inc. a good stock to buy?

The fair value guage provides a quick view whether SQL is over valued or under valued. Whether SeqLL Inc. is cheap or expensive depends on the assumptions which impact SeqLL Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SQL.

What is SeqLL Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Sun Mar 31 2024, SQL's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 19.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SQL PE ratio will change depending on the future growth rate expectations of investors.